
887 assessed for eligibility
181 excluded
706 randomized
350 assigned to D-VMP (ITT)
317 (90.6%) completed EORTC QLQ-C30
316 (90.3%) completed EQ-5D-5L
356 assigned to VMP (ITT)
327 (92.4%) completed EORTC QLQ-C30
325 (91.9%) completed EQ-5D-5L
346 received assigned intervention
354 received assigned intervention
100 discontinued intervention
246 Ongoing
• 17 Cycles 1-9
• 229 Cycles 10+
0 Completed
117 discontinued intervention
• 47 Progressive disease
• 33 Adverse event
• 8 Death
• 29 Other
17 Ongoing
220 Completed
Cycles 1-9
67 Discontinued intervention
• 23 Progressive disease
• 17 Adverse event
• 11 Death
• 16 Other
Cycles 10+
33 Discontinued intervention
• 30 Progressive disease
• 0 Adverse event
• 2 Death
• 1 Other